REPLICEL LIFE SCIENCE ORD - REPCF STOCK NEWS

RepliCel Life Sciences announced significant patent milestones for its DermaPrecise™ technology, receiving grants in the U.S. (Patent No. 11,311,684) and Japan (Patent No. 6718472B2), which are crucial markets for the company's cell therapies. Additional patents were granted in New Zealand and South Africa, with notices of allowance in China and Mexico. These patents enhance the clinical and commercial value of RepliCel's injection technologies, supporting upcoming Phase 2 studies in China and expanding the potential of its regenerative cell therapies.

RepliCel Life Sciences has announced breakthrough results from Innovacell indicating that its DermaPrecise™ Injector achieves over 99% cell viability post-injection, with cells remaining viable for up to 90 minutes. This electrically controlled injector ensures precise depth and dose, minimizing harmful shear forces on cells. The DermaPrecise™ system is expected to enhance the efficacy of its cell therapies, notably the RCH-01 for hair restoration. This advancement addresses significant challenges in cell delivery, supporting the company’s commitment to improving clinical outcomes in regenerative medicine.

RepliCel Life Sciences Inc. (OTCPINK:REPCF) announced the successful inspection of its NBDS cell therapy manufacturing facility in Austria by Japan's PMDA. This milestone, a prerequisite for clinical studies in Japan under the Act for the Safety of Regenerative Medicine, positions RepliCel for upcoming trials of RCT-01 and RCS-01, aimed at treating chronic tendinopathy and skin rejuvenation. Notably, this certification would be the first of its kind for a facility outside Asia. RepliCel continues to collaborate with key partners and regulatory agencies in Japan for clinical evaluations and commercial strategies.

RepliCel Life Sciences Inc. (OTC PINK: REPCF) announced successful testing of its DermaPrecise^TM injector prototype by independent dermatology research experts at Monasterium Laboratory GmbH. The tests confirmed the device's ability to deliver controlled, consistent intradermal and subcutaneous injections in donated human skin tissue, surpassing set objectives for volume and depth.

With plans for commercial launch, RepliCel emphasizes the significance of these independent validations in demonstrating the injector's precision and efficacy to potential clinicians.

RepliCel Life Sciences (OTC PINK:REPCF) announced a new patent application and the granting of patents for its DermaPrecise™ technologies in Japan, Brazil, and Mexico. The DermaPrecise™ Injector offers advanced precision in dermal injections, enhancing the product's potential for various applications including skin rejuvenation and chronic tendon treatment. Future regulatory approvals are being pursued, with products in production for clinical testing. RepliCel's involvement in Japan's regenerative medicine market signifies a strategic expansion and innovation in therapeutic solutions.

RepliCel Life Sciences (OTC PINK:REPCF) has finalized an investment from MainPointe Pharmaceuticals, closing the final tranche that raised CAD$998,921 by issuing 1,479,882 common shares. This brings the total investment to CAD$2,698,921, resulting in 3,986,684 shares issued at CAD$0.675 each. The partnership facilitates regulatory submission to the FDA for RepliCel's injector and consumables. RepliCel is focused on regenerative medicine, targeting aesthetic and orthopedic issues with its cell therapy products. The company maintains rights for its products outside of China.

RepliCel Life Sciences has announced the termination of its license agreement with Shiseido due to an ongoing dispute over a cell therapy technology license for treating hair loss. This legal decision is part of RepliCel's arbitration process with Shiseido under the International Center for Dispute Resolution. The company retains rights to its RCH-01 product outside Asia and continues product development with strategic partners in the U.S. and China. RepliCel's therapies have been tested on over 100 patients across various countries.

RepliCel Life Sciences Inc. has shipped DermaPrecise™ Injector prototypes to Monasterium Laboratory in Germany for validation studies using donated human skin tissue. This independent testing aims to assess injection parameters and depth precision, crucial for the commercial launch of the DermaPrecise™ product line. The study will involve various injection depths and biodistribution analysis to enhance efficacy in clinical treatments. RepliCel's cell therapy products target conditions like skin rejuvenation and tendon repair and are supported by strategic partners across the globe.